Shots:

• The US FDA has granted premarket approval of TransMedics’s OCS liver system for use with organs from DBD and DCD. The approval is based on the results of the OCS Liver PROTECT trial
• The OCS liver system is designed to preserve and monitor hemodynamics and metabolic function which allows ex-vivo assement of liver allografts from DBD and DCD donor livers
• The company provides its OCS perfusion technology for lung- heart and liver transplantation & also plans to expand commercial activities with all three OCS systems in Q4’21

  | Ref: Transmedics | Image: PR Newswire